{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:12:37Z","timestamp":1753891957828,"version":"3.41.2"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>We retrospectively analyzed SARS-CoV-2 vaccination antibody responses in a cohort of 273 patients with lymphoproliferative disorders or plasma cell dyscrasias who were seen at a single tertiary cancer center. Semi-quantitative anti-spike protein serologic testing was performed with enzyme immunoassay method. We found that the antibody response rate to SARS-CoV-2 vaccination was 74.7% in our patient cohort with no difference based on gender, age or race. The highest response rate was found in patients with Multiple Myeloma (MM) (95.5%). The response rates found in Diffuse Large B-Cell Lymphoma (DLBCL), Chronic Lymphocytic Leukemia (CLL), and Low-Grade Non-Hodgkin Lymphoma (LG-NHL) were 73.2%, 61.5% and 53% respectively. We also evaluated the effects of receiving active chemo-immunotherapy on SARS-CoV-2 vaccination antibody response. We found that the patients on treatment had lower response than the patients off treatment (62.1% versus 84.4% p&amp;lt;0.001). Thirty-four of 58 LG-NHL patients were receiving anti-lymphoma treatment with a lower SARS-CoV-2 vaccination response as compared to the patients who were not on treatment (29.4% v 87.5% p&amp;lt;0.001). We observed a similar pattern in CLL patients receiving treatment (48.1 v 76.0 p:0.049). We found that only disease type and treatment status (on-treatment vs. off- treatment), but not gender, age or race were significant predictors of non-response in the multivariable logistic regression model. The interaction between disease type and treatment status was not statistically significant by multivariate analysis. In conclusion, receiving anti-cancer treatment was found to play a significant role in decreasing the response to COVID-19 vaccination.<\/jats:p>","DOI":"10.3389\/fonc.2022.840451","type":"journal-article","created":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T05:30:06Z","timestamp":1657171806000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Antibody Response to SARS-CoV-2 Vaccination in Patients With Lymphoproliferative Disorders and Plasma Cell Dyscrasias: Anti-Lymphoma Therapy as a Predictive Biomarker of Response to Vaccination"],"prefix":"10.3389","volume":"12","author":[{"given":"Carol","family":"Gung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercy","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullateef","family":"Abdulkareem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine A.","family":"Belden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierluigi","family":"Porcu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ubaldo","family":"Martinez-Outschoorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam F.","family":"Binder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inna","family":"Chervenova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onder","family":"Alpdogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Single-Dose Ad26.Cov2.S Vaccine Against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/vaccines9010061","article-title":"Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans","volume":"9","author":"Cagigi","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.16477","article-title":"Prevalence of Immunosuppression Among US Adults, 2013","volume":"316","author":"Harpaz","year":"2016","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.7489","article-title":"Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients","volume":"325","author":"Boyarsky","year":"2021","journal-title":"JAMA"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.7326\/L21-0282","article-title":"Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series","volume":"174","author":"Werbel","year":"2021","journal-title":"Ann Intern Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00213-8","article-title":"Safety and Immunogenicity of One Versus Two Doses of the COVID-19 Vaccine BNT162b2 for Patients With Cancer: Interim Analysis of a Prospective Observational Study","volume":"22","author":"Monin","year":"2021","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1101\/2021.04.06.21254949","article-title":"Suboptimal Response to COVID-19 mRNA Vaccines in Hematologic Malignancies Patients","author":"Agha","year":"2021","journal-title":"medRxiv"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.06.014","article-title":"Highly Variable SARS-CoV-2 Spike Antibody Responses to Two Doses of COVID-19 RNA Vaccination in Patients With Multiple Myeloma","volume":"39","author":"Van Oekelen","year":"2021","journal-title":"Cancer Cell"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.07.012","article-title":"Antibody Response to SARS-CoV-2 Vaccines in Patients With Hematologic Malignancies","volume":"39","author":"Greenberger","year":"2021","journal-title":"Cancer Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi320","article-title":"Single Agent Rituximab in Patients With Follicular or Mantle Cell Lymphoma: Clinical and Biological Factors That are Predictive of Response and Event-Free Survival as Well as the Effect of Rituximab on the Immune System: A Study of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"16","author":"Ghielmini","year":"2005","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2006.08.009","article-title":"B Cell Reconstitution After Rituximab Treatment of Lymphoma Recapitulates B Cell Ontogeny","volume":"122","author":"Anolik","year":"2007","journal-title":"Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent Infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcu094","article-title":"Hypogammaglobulinaemia After Rituximab Treatment-Incidence and Outcomes","volume":"107","author":"Makatsori","year":"2014","journal-title":"QJM"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-372649","article-title":"Rituximab Blocks Protective Serologic Response to Influenza A (H1N1) 2009 Vaccination in Lymphoma Patients During or Within 6 Months After Treatment","volume":"118","author":"Yri","year":"2011","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ejca.2020.06.017","article-title":"Could Anti-CD20 Therapy Jeopardise the Efficacy of a SARS-CoV-2 Vaccine","volume":"136","author":"Houot","year":"2020","journal-title":"Eur J Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279216","article-title":"Humoral Serologic Response to the BNT162b2 Vaccine is Abrogated in Lymphoma Patients Within the First 12 Months Following Treatment With Anti-CD2O Antibodies","volume":"107","author":"Gurion","year":"2021","journal-title":"Haematologica"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012443","article-title":"Impaired Humoral Responses to COVID-19 Vaccination in Patients With Lymphoma Receiving B-Cell-Directed Therapies","volume":"138","author":"Ghione","year":"2021","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.07.016","article-title":"Antibody and T Cell Immune Responses Following mRNA COVID-19 Vaccination in Patients With Cancer","volume":"39","author":"Ehmsen","year":"2021","journal-title":"Cancer Cell"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01418-8","article-title":"Impact of Anti-CD20 Monoclonal Antibodies on Serologic Response to BNT162b2 Vaccine in B-Cell Non-Hodgkin's Lymphomas","volume":"36","author":"Marchesi","year":"2021","journal-title":"Leukemia"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1864359","article-title":"The Importance of Immunoparesis in Multiple Myeloma","volume":"62","author":"Gertz","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0163-4","article-title":"Characterisation of Immunoparesis in Newly Diagnosed Myeloma and its Impact on Progression-Free and Overall Survival in Both Old and Recent Myeloma Trials","volume":"32","author":"Heaney","year":"2018","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2017.11.014","article-title":"Subcutaneous Immunoglobulins in Patients With Multiple Myeloma and Secondary Hypogammaglobulinemia: A Randomized Trial","volume":"191","author":"Vacca","year":"2018","journal-title":"Clin Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.840451\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T05:30:08Z","timestamp":1657171808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.840451\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,7]]},"references-count":25,"alternative-id":["10.3389\/fonc.2022.840451"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.840451","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2022,7,7]]},"article-number":"840451"}}